Leo Pharma Sues Glenmark to Block Copy of Plaque-Psoriasis Drug

Closely held Leo Pharma said Glenmark’s proposed generic version of a foam treatment for plaque psoriasis infringes five patents for Enstilar.

• Leo is seeking a court order blocking copies until the patents have expired and to collect cash compensation if copies are made before then, according to complaint filed Wednesday in federal court in Wilmington, Delaware
• Patents were issued in April, May, June and July of this year, complaint says, and expire in June 2031, according to supplemental filing
• NOTE: Leo Pharma Expects to Get New Owner This Year, Finans Says
• NOTE: Leo Pharma Looks Into a Possible IPO, ...